Startup profile · funding coverage
VectorY Therapeutics funding, valuation and investors
Amsterdam clinical-stage biotech developing one-time vectorized antibody treatments for ALS and other neurodegenerative diseases.
Verified company research · funding, investors and latest developments
Keep track of VectorY Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Mixed financing package (not all equity; no Series B designation)
€74.5M combined financing INCLUDING €30M EIB convertible loan and €7M Invest-NL equity; other component allocations not fully disclosed · November 11, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Amsterdam, Netherlands
Investors in latest funding
Other: European Investment Bank , Invest-NL , Angelini Ventures , Forbion , EQT Life Sciences , Insight Partners
Overview
VectorY builds adeno-associated-virus (AAV) delivery systems that carry genetic instructions for antibodies into nerve cells, where they are intended to be produced over time. Its first candidate VTx-002 targets pathological TDP-43 in amyotrophic lateral sclerosis (ALS), and PIONEER-ALS is an open-label Phase 1/2 dose-escalation study evaluating safety, tolerability, pharmacokinetics and exploratory biomarkers.
It has not established clinical efficacy or received marketing approval. November 11, 2026 financing of €74.5M includes a €30M convertible European Investment Bank loan; €7M Invest-NL is disclosed as equity.
Original sources: https://www.vectorytx.com/news/vectory-expands-pioneer-als-phase-12-clinical-trial-size-4jeae ; https://www.eib.org/fr/press/all/2026-413-dutch-biotech-fighting-als-and-other-neuro-degenerative-diseases-gets-european-backing ; https://www.invest-nl.nl/en/news/invest-nl-invests-7-million-in-developing-new-technology-to-combat-als
Why VectorY Therapeutics is interesting
Its AAV-delivered intracellular antibody approach could sustain antibody production in the central nervous system, but human safety and disease-modifying efficacy remain to be established. A November 2026 €74.5M financing package includes €30M EIB convertible debt, so it is not an all-equity Series B.
Product & use cases
RESEARCH-STAGE, NOT AN APPROVED PRODUCT. An illustrative scientific pathway: researchers design an intracellular antibody against misfolded TDP-43; package genetic instructions in an AAV delivery vehicle; administer investigational vector in a supervised clinical study; seek sustained antibody expression in relevant CNS cells; assess dosing, safety, drug-exposure, neurofilament light chain, TDP-43 biomarkers and exploratory ALS functional outcomes. The company is testing this approach in PIONEER-ALS, not offering it commercially.
- Investigational VTx-002 for ALS: expanded open-label Phase 1/2 from 12 to 36 participants; exploratory efficacy is not proof of disease modification.
- Preclinical VTx-003 for Huntington's disease, VTx-004 for frontotemporal dementia, and VTx-005 for Alzheimer's; approval, pricing and reimbursement unknown.
- AAV and antibody manufacturing capabilities underpin planned repeat applications of the platform; scale and long-term safety remain to be demonstrated.
Key facts
- November 11, 2026 financing package €74.5M combines equity and EIB convertible loan; the latter is €30M, not equity.
- Invest-NL discloses €7M equity contribution; no total-equity split or valuation confirmed.
- PIONEER-ALS open-label Phase 1/2 studies safety and exploratory efficacy; 36-participant expansion announced September 2026.
Funding history (newest first)
Mixed financing package (not all equity; no Series B designation)
2026-11-11 €74.5M combined financing INCLUDING €30M EIB convertible loan and €7M Invest-NL equity; other component allocations not fully disclosed- European Investment Bank (participant)
- Invest-NL (participant)
- Angelini Ventures (participant)
- Forbion (participant)
- EQT Life Sciences (participant)
- Insight Partners (participant)
Source: Read source · vectorytx.com
Series A
2023-11-13 €129M equity financing (2023)- Forbion Growth Opportunities Fund (lead)
- EQT Life Sciences (lead)
- Insight Partners (participant)
- MRL Ventures Fund (participant)
- BioGeneration Ventures (participant)
Source: Read source · vectorytx.com
Competitive landscape
Edge: AAV-encoded intracellular antibodies may provide local sustained expression with one administration rather than repeated doses, in theory; durability, immune response, correct CNS targeting and clinical outcomes are unproven.
-
Riluzole and edaravone incumbent
Approved ALS drugs with different mechanisms; clinical comparison against VTx-002 unavailable.
-
Qalsody (tofersen) alternative
Antisense treatment for SOD1-mutated ALS, targeting a genetically defined subgroup rather than TDP-43 pathology.
-
Other AAV gene therapies for ALS direct
Compete on delivery, target and safety, but cross-trial efficacy claims are premature.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.